🐯虎嗅•Stalecollected in 30m
New regulation bans AI from replacing pharmacists in prescription review
💡Critical regulatory update on AI's role in healthcare: human-in-the-loop is now a legal requirement for prescription rev
⚡ 30-Second TL;DR
What Changed
The new guidelines mandate that prescription reviews must be performed by licensed pharmacists, not AI.
Why It Matters
This regulation sets a legal precedent for AI in healthcare, emphasizing that while AI can assist, human accountability remains mandatory for high-risk medical decisions.
What To Do Next
If developing AI for medical diagnostics or prescription workflows, ensure your product includes a 'human-in-the-loop' architecture to meet strict regulatory compliance.
Who should care:Developers & AI Engineers
Key Points
- •The new guidelines mandate that prescription reviews must be performed by licensed pharmacists, not AI.
- •Regulators are shifting toward 'smart supervision' using AI and big data to monitor platform compliance.
- •The 'mystery shopper' mechanism is recommended to audit the entire online drug sales chain, including prescription validity.
🧠 Deep Insight
Web-grounded analysis with 13 cited sources.
🔑 Enhanced Key Takeaways
- •The new guidelines are part of a broader effort to address long-standing safety and quality risks in China's rapidly expanding online drug retail market, which exceeded 80 billion yuan ($11.8 billion) in 2025.
- •The regulation also explicitly prohibits the reuse of the same prescription for multiple purchases and requires online drug retailers to manage pharmacists' daily review workloads to prevent irrational or excessive medication use.
- •This national ban on AI in prescription review follows earlier, more localized prohibitions, such as draft rules in Beijing (August 2023) and a ban in Hunan province (February 2025), indicating a trend towards stricter human oversight in online medical services.
- •The "smart supervision" framework, led by the National Medical Products Administration (NMPA), aims to leverage AI and big data for comprehensive lifecycle oversight, including risk-based inspections, data-driven planning, and intelligent identification of compliance issues across drugs, medical devices, and cosmetics.
🔮 Future ImplicationsAI analysis grounded in cited sources
The regulation will likely accelerate the development of AI tools for assisting pharmacists rather than replacing them.
While AI is banned from replacing pharmacists in prescription review, existing regulations allow AI to aid doctors in tasks like reading medical images, organizing data, and formulating treatment plans, suggesting a shift towards assistive AI.
Online pharmacies will face increased operational costs and complexity due to the mandate for human pharmacist review and stricter compliance.
Requiring licensed pharmacists for every prescription review, limiting their workload, and implementing real-name purchases and traceability systems will necessitate more human resources and robust compliance infrastructure for online platforms.
The "smart supervision" framework will lead to more sophisticated and proactive regulatory enforcement in China's online drug market.
The NMPA's roadmap includes using AI and big data for risk-based inspections, data-driven planning, and intelligent identification of compliance issues, indicating a move towards continuous and data-driven oversight.
⏳ Timeline
2019
China amended the Drug Administration Law to permit online sale of prescription drugs with limitations, marking its first national congress-level regulatory policy on online pharmacy regulation.
2020-04
An AI-based internet hospital pharmacy service mode was launched at Eye & ENT Hospital of Fudan University, utilizing AI for prescription preview.
2022-12-01
China's Administrative Measures for Supervising Online Sales of Drugs (Decree 58) took effect, allowing nationwide online sales of prescription drugs, with requirements for licensed pharmacists to review and dispense prescriptions.
2023-08-21
Beijing health authorities released a draft rule planning to ban AI-generated online medical prescriptions.
2025-02-25
Hunan province health authorities issued a statement strictly prohibiting the use of AI and other automated methods to generate prescriptions for online clinics.
2026-05-25
China's top drug regulator issued new guidelines explicitly banning AI from conducting pharmacist reviews of prescriptions and prohibiting prescription reuse.
📎 Sources (13)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
📰
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 虎嗅 ↗